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Abstract
Introduction
Opioid addiction in the United States has become a major public 
health crisis. The Centers for Disease Control and Prevention (CDC) 
estimates that 134 people die from opiate overdose each day. 
Neonates who are heavily exposed to opiates in utero often 
experience withdrawal upon parturition, a condition called neonatal 
abstinence syndrome (NAS). NAS increased by 500% in the US 
between 2000 and 2012. Treatment protocol supports the use of MAT 
to prevent NAS. Currently, methadone is administered to prevent 
pregnant women from abusing opiate substances, namely heroin or 
prescription opiates. However, a growing body of evidence supports 








Although buprenorphine is not the standard of care for pregnant 
women with OUD, it should be considered as an alternative to 
methadone maintenance therapy. NAS is reduced with 
buprenorphine compared to methadone treatment, though more 
women sustain MAT with methadone. Because NAS is less 
severe with buprenorphine MAT compared to methadone MAT, 
length of stay (LOS) is less with buprenorphine exposed 
neonates and thus is a more effective way to spend the very 
limited healthcare dollars that exist for these patients. In addition, 
MAT drug choice should be individual. Finally, if one MAT drug 
is failed, another should be initiated.
Methadone Versus Buprenorphine
The purpose of this research and systematic literature review is to determine 
which pharmacotherapeutic agent, methadone or buprenorphine, leads to 
better outcomes in cases of pregnant mothers with opioid use disorder 
(OUD). Outcomes considered are maternal compliance, neonatal abstinence 
syndrome severity, and neonatal length of hospital stay. In the review, 
PubMed, Clinical Key, Cochrane Database of Systematic Reviews, and 
DynaMed Plus were searched. Key terms searched were “methadone, 
buprenorphine, pregnancy”, “opioids, pregnancy”, “neonatal abstinence 
syndrome” and “medication assisted treatment, pregnancy”. Several studies 
were excluded, as their study population was not specified to have diagnosed 
OUD in pregnancy. The drawbacks to many of the studies is the 
inconsistencies in study conditions, and very small sample sizes. Much of 
the research presented shows evidence for the use of buprenorphine in the 
treatment of OUD in pregnancy. Buprenorphine seems to be a better 
medication assisted treatment (MAT) for the neonate in terms of reduced 
neonatal abstinence syndrome (NAS) and reduced length of hospital stay 
postpartum, while methadone still performs better for adherence for the 
mother. More research still needs to be done in order to demonstrate 
buprenorphine’s superior efficacy compared to methadone use in pregnant 
patients with OUD. 
Keywords: MAT, methadone, buprenorphine, pregnancy, OUD, opioid, 
addiction, NAS, neonate
In pregnant patients with OUD, how effective is methadone 
compared to buprenorphine in the reduction of NAS? 
In pregnant patients with OUD, how effective is methadone 
compared to buprenorphine in the reduction in length of hospital 
stay for neonates?
In pregnant patients with OUD, how effective is methadone 
compared to buprenorphine in retention on MAT and prevention 
of relapse?
Maintenance treatment provides a steady concentration of opiate 
in the pregnant woman’s blood and so prevents the adverse effects 
on the fetus of repeated withdrawals (Minozzi et al., 2013). In 
conjunction with psychosocial and cognitive behavioral therapy, 
MAT is endorsed over medically assisted withdrawal or 
abstinence for pregnant women with OUD by the Substance 
Abuse and Mental Health Services Administration and the 
American College of Obstetricians and Gynecologists 
Committee (Tran, Griffin, Stone, Vest, & Todd, 2017).
• Fowler et al., (2013) found that buprenorphine led to better 
outcomes for neonates but had dropout rates of 56.4% 
compared to methadone. Also, buprenorphine led to a cost 
savings of over $12.4 million healthcare dollars. 
• Jansson et al., (2017) found that of mothers treated with 
buprenorphine, had a high dropout rate, and total length of 
hospitalization of neonates was 14.7 days on average.
• A Cochrane review found that mothers on methadone therapy 
are less likely to drop out of the study (RR 0.64, 95% CI 0.41 to 
1.01, n=223) compared to those on buprenorphine. There was 
no significant difference in the number of newborns treated for 
NAS, but evidence is considered very low (RR 1.22, 95% CI 
0.89 to 1.67, three studies, n=166) (Minozzi et al., 2013).
• The MOTHER study by Jones et al., (2010) showed 
discontinuation of treatment occurred in 18% of women in 
methadone treatment and 33% of women in buprenorphine 
treatment (p=0.02). The number of neonates requiring NAS 
treatment was not significantly different between groups 
(p=0.26). Neonates from the buprenorphine group needed 89% 
less morphine than those exposed to methadone (p<0.0091) and 
spent 43% less time in the hospital (p<0.0091). 
• Pregnant women addicted to intravenous heroin were studied in 
a five-year randomized prospective comparative study by 
Binder and Vavřinková (2008). The degree of NAS severity was 
9.2 in the buprenorphine group, 11 in the heroin group, and 17.8 
in the methadone group (buprenorphine to methadone 
p<0.000001, heroin to methadone p<0.00001).
North Dakota experiences opioid addiction across the state but 
faces challenges for patients to get the care they need due to a lack 
of specialists and a vastness of rural geography. Since stigma still 
exists with MAT, providers should be given the tools to screen, 
refer, and care for pregnant mothers with OUD. Withdrawal during 
pregnancy should be discouraged, and personal judgements 
withheld.
• Project ECHO or “Extension for Community Healthcare 
Outcomes” is a hub and spoke model used to train rural providers 
with resources and information through video conferencing. 
Project ECHO is focused on the opioid epidemic in North Dakota 
and provides video sessions weekly from experts and specialists in 
academic or health care centers to primary care teams in rural parts 
of the state.
• Champion Prescriber initiative expands access to MAT in North 
Dakota. These providers provide MAT treatment and overdose 
prevention education, collaborate with providers in project ECHO, 
and provide training on the use of Naloxone. 
• The First Steps to Healthy Babies service provided by Sanford in 
Bemidji, MN aims to help women have safe and healthy 
pregnancies and encourages sobriety with support services. They 
have seen a significant increase in the number of mothers who 
undergo MAT during pregnancy and are able to return home with 
their infant.
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Statement of the Problem
Methadone is the current standard of care for the use of MAT in 
pregnant women with OUD. Studies are needed to show the safety 
and efficacy of other treatment options such as buprenorphine for 
this patient population. 
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